FluoGuide Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

FluoGuideDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -27.7% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 46.7% pro Jahr.

Wichtige Informationen

-27.7%

Wachstumsrate der Gewinne

-18.1%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	0.7%
Wachstumsrate der Einnahmen	-46.7%
Eigenkapitalrendite	-618.3%
Netto-Marge	-9,494.3%
Nächste Ertragsaktualisierung	29 Aug 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie FluoGuide Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OM:FLUO Einnahmen, Ausgaben und Erträge (DKK Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	0	-36	41
31 Dec 23	0	-38	44
30 Sep 23	0	-37	39
30 Jun 23	0	-34	38
31 Mar 23	3	-33	47
31 Dec 22	7	-27	39
30 Sep 22	8	-25	36
30 Jun 22	10	-26	40
31 Mar 22	13	-24	40
31 Dec 21	10	-24	38
30 Sep 21	8	-22	36
30 Jun 21	6	-17	29
31 Mar 21	0	-18	27
31 Dec 20	0	-17	25
30 Sep 20	0	-14	12
30 Jun 20	0	-16	11
31 Mar 20	0	-12	11
31 Dec 19	0	-10	11

Qualität der Erträge: FLUO ist derzeit unrentabel.

Wachsende Gewinnspanne: FLUO ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: FLUO ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 32% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von FLUO verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: FLUO ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (3%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: FLUO hat eine negative Eigenkapitalrendite (-618.31%), da es derzeit unrentabel ist.

FluoGuide Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

Recent updates

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma

FluoGuide Appoints Henrik Moltke as Chief Financial Officer, Effective December 2020

New 90-day high - kr.40.00

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren